Detection of thyroid-stimulating hormone receptor and Gsα mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis

The actual frequency of constitutively activating thyrotropin receptor or Gsα mutations in toxic thyroid nodules (TTNs) remains controversial as considerable variation in the prevalence of these mutations has been reported. We studied a series of 75 consecutive TTNs and performed mutation screening by the more sensitive method of denaturing gradient gel electrophoresis (DGGE) in addition to direct sequencing. Furthermore, the likelihood of somatic mutations occurring in genes other than that for the thyroid-stimulating hormone receptor (TSHR) and exons 7–9 of the Gsα protein gene was determined by clonality analysis of TTNs, which did not harbor mutations in the investigated genes. In 43 of 75 TTNs (57%) constitutively active TSHR mutations were identified. Six TSHR mutations were detected only by DGGE, underlining the importance of a sensitive screening method. Novel, constitutively activating mutations were identified at positions 425 (Ser→Leu) and 512 (Leu→Glu/Arg). Furthermore, a new base substitution was detected at position Pro639Ala (CCA→GCA). Ten of 20 TSHR or Gsα mutation negative cases (50%) showed nonrandom X-chromosome inactivation, indicating clonal origin. In conclusion, somatic, constitutively activating TSHR mutations appear to be a major cause of TTNs (57%), while mutations in Gsα play a minor role (3%). The mutation negative but clonal cases indicate a probable involvement of somatic mutations other than in the TSH receptor or Gsα genes as the molecular cause of these hot nodules.

[1]  H. Namba,et al.  Expression and regulation of G protein-coupled receptor kinase 5 and beta-arrestin-1 in rat thyroid FRTL5 cells. , 1996, Thyroid : official journal of the American Thyroid Association.

[2]  H. Bourne,et al.  Increased stimulatory G protein in neoplastic human thyroid tissues. , 1991, Surgery.

[3]  R. Paschke,et al.  Somatic Mutations in the Thyrotropin Receptor Gene and Not in the Gsα Protein Gene in 31 Toxic Thyroid Nodules1 , 1997 .

[4]  R. Paschke,et al.  The extracellular thyrotropin receptor domain is not a major candidate for mutations in toxic thyroid nodules. , 1998, Thyroid : official journal of the American Thyroid Association.

[5]  J. Benovic,et al.  G‐Protein–coupled receptor kinase expression in hypertension , 1999, Clinical pharmacology and therapeutics.

[6]  R. Paschke,et al.  Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. , 1994, The Journal of clinical endocrinology and metabolism.

[7]  M. Parmentier,et al.  Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism. , 1992, The EMBO journal.

[8]  J. Parma,et al.  Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas , 1993, Nature.

[9]  H. Zoghbi,et al.  Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. , 1992, American journal of human genetics.

[10]  M. Böhm,et al.  Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. , 1994, Circulation research.

[11]  P. Rocmans,et al.  Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. , 1997, The Journal of clinical endocrinology and metabolism.

[12]  R. Paschke,et al.  Sporadic congenital hyperthyroidism due to a spontaneous germline mutation in the thyrotropin receptor gene. , 1997, The Journal of clinical endocrinology and metabolism.

[13]  R. Paschke,et al.  DGGE is more sensitive for the detection of somatic point mutations than direct sequencing. , 1999, BioTechniques.

[14]  Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. , 1996, The Journal of clinical endocrinology and metabolism.

[15]  P. Rocmans,et al.  Pathogenesis of autonomous thyroid nodules: in vitro study of iodine and adenosine 3',5'-monophosphate metabolism. , 1988, The Journal of clinical endocrinology and metabolism.

[16]  S. Filetti,et al.  Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. , 1996, The Journal of clinical endocrinology and metabolism.

[17]  R. Paschke,et al.  Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. , 1997, The Journal of clinical endocrinology and metabolism.

[18]  L. Iacovelli,et al.  GRK2 and beta-arrestin 1 as negative regulators of thyrotropin receptor-stimulated response. , 1996, Molecular endocrinology.

[19]  T. Dryja,et al.  Defects in the rhodopsin kinase gene in the Oguchi form of stationary night blindness , 1997, Nature Genetics.

[20]  S. Vatner,et al.  Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. , 1996, Circulation research.

[21]  R. Paschke,et al.  The thyrotropin receptor in thyroid diseases. , 1997, The New England journal of medicine.

[22]  S. Vatner,et al.  Adverse Effects of Chronic Endogenous Sympathetic Drive Induced by Cardiac Gsα Overexpression , 1996 .

[23]  Gunnar Sigurdsson,et al.  High incidence of Plummer's disease in the elderly population in a low iodine intake area, versus high incidence of Graves' disease in the young in a high iodine intake area , 1991 .

[24]  P. Kamoun,et al.  Quantitative non-radioactive clonality analysis of human leukemic cells and progenitors using the human androgen receptor (AR) gene. , 1995, Leukemia.

[25]  R. Paschke,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Clonal Origin of Toxic Thyroid Nodules with Constitutively Activating Thyrotropin Receptor Mutations* , 2022 .

[26]  A. Porcellini,et al.  Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. , 1994, The Journal of clinical endocrinology and metabolism.

[27]  S. Rhee,et al.  Regulation of inositol phospholipid-specific phospholipase C isozymes. , 1992, The Journal of biological chemistry.

[28]  N. Ishikawa,et al.  Rarity of oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in Japan. , 1995, The Journal of clinical endocrinology and metabolism.

[29]  Melvin I. Simon,et al.  Diversity of G proteins in signal transduction , 1991, Science.

[30]  A. Allgeier,et al.  Germline mutations in the thyrotropin receptor gene cause non–autoimmune autosomal dominant hyperthyroidism , 1994, Nature Genetics.

[31]  R. Iyengar Molecular and functional diversity of mammalian Gs‐stimulated adenylyl cyclases , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  S. Filetti,et al.  Genetic alterations in thyroid hyperfunctioning adenomas. , 1995, The Journal of clinical endocrinology and metabolism.

[33]  M. García-Delgado,et al.  Higher sensitivity of denaturing gradient gel electrophoresis than sequencing in the detection of mutations in DNA from tumor samples. , 1998, BioTechniques.

[34]  E. Kawasaki,et al.  Two G protein oncogenes in human endocrine tumors. , 1990, Science.

[35]  J. Bijlsma,et al.  Decreased expression and activity of G‐protein‐coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  J. Parma,et al.  A germline mutation of the thyrotropin receptor gene associated with thyrotoxicosis and mitral valve prolapse in a Chinese family. , 1999, The Journal of clinical endocrinology and metabolism.

[37]  H. Tamir,et al.  G-protein beta gamma forms: identity of beta and diversity of gamma subunits. , 1991, Biochemistry.

[38]  N. Lemoine,et al.  Activating point mutations of the gsp oncogene in human thyroid adenomas , 1991, Molecular carcinogenesis.

[39]  P. Ping,et al.  Increased expression of adenylylcyclase type VI proportionately increases beta-adrenergic receptor-stimulated production of cAMP in neonatal rat cardiac myocytes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  F. Cetani,et al.  Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma. , 1998, The Journal of clinical endocrinology and metabolism.

[41]  R. Lefkowitz,et al.  Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. , 1998, Science.

[42]  T. Mori,et al.  Constitutive activation of the thyrotropin receptor by mutating CYS-636 in the sixth transmembrane segment. , 1996, Biochemical and biophysical research communications.

[43]  M. Parmentier,et al.  Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. , 1989, Biochemical and biophysical research communications.

[44]  R. Paschke,et al.  Identification of a new thyrotropin receptor germline mutation (Leu629Phe) in a family with neonatal onset of autosomal dominant nonautoimmune hyperthyroidism. , 1997, The Journal of clinical endocrinology and metabolism.